| Healthmax Progressive Medicine | |
|
7060 Valley Creek Plz Ste 121 Woodbury MN 55125-2269 | |
| (651) 735-8646 | |
| (651) 730-9210 |
| Full Name | Healthmax Progressive Medicine |
|---|---|
| Speciality | Clinic/Center |
| Location | 7060 Valley Creek Plz Ste 121, Woodbury, Minnesota |
| Authorized Official Name and Position | Christopher Thomas Drews (PRESIDENT) |
| Authorized Official Contact | 6517358646 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Healthmax Progressive Medicine 7060 Valley Creek Plz Ste 121 Woodbury MN 55125-2269 Ph: (651) 735-8646 | Healthmax Progressive Medicine 7060 Valley Creek Plz Ste 121 Woodbury MN 55125-2269 Ph: (651) 735-8646 |
| NPI Number | 1407337629 |
|---|---|
| Provider Enumeration Date | 08/25/2018 |
| Last Update Date | 07/28/2022 |
| Medicare PECOS PAC ID | 3375894132 |
|---|---|
| Medicare Enrollment ID | O20180928000145 |
News Archive
Researchers at the University of Pennsylvania School of Medicine have determined how serotonin decreases the body's sensitivity to light and that exposure to constant darkness leads to a decrease in serotonin levels in the brain of fruit flies.
Diabetes in Control (http://www.diabetesincontrol.com), an e-newsletter dedicated to keeping clinicians current with the rapid changes in diabetes care, expands its quest to provide them with the best tools for their practice.
A significant discovery in the development of next-generation antibiotics has been made by Scottish biotechnology company Aquapharm.
A new Associated Press-GfK poll shows the strong emotions against President Barack Obama's health overhaul may be subsiding. Meanwhile, even as the industry's trade groups remain somewhat neutral on the law's future, pre-repeal groups are stepping up lobbying efforts.
ImmunoCellular Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has given clearance to a physician sponsored investigative new drug (IND) application to initiate a Phase I clinical trial of ICT-121, IMUC's novel dendritic-cell-based vaccine targeting CD-133, an antigen that is highly expressed by multiple solid tumors.
› Verified 8 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1407337629 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 261QM1300X | Clinic/center - Multi-specialty | (* (Not Available)) | Primary |
| Provider Name | Christopher Thomas Drews |
|---|---|
| Provider Type | Practitioner - Chiropractic |
| Provider Identifiers | NPI Number: 1467518373 PECOS PAC ID: 8224073135 Enrollment ID: I20050622000189 |
News Archive
Researchers at the University of Pennsylvania School of Medicine have determined how serotonin decreases the body's sensitivity to light and that exposure to constant darkness leads to a decrease in serotonin levels in the brain of fruit flies.
Diabetes in Control (http://www.diabetesincontrol.com), an e-newsletter dedicated to keeping clinicians current with the rapid changes in diabetes care, expands its quest to provide them with the best tools for their practice.
A significant discovery in the development of next-generation antibiotics has been made by Scottish biotechnology company Aquapharm.
A new Associated Press-GfK poll shows the strong emotions against President Barack Obama's health overhaul may be subsiding. Meanwhile, even as the industry's trade groups remain somewhat neutral on the law's future, pre-repeal groups are stepping up lobbying efforts.
ImmunoCellular Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has given clearance to a physician sponsored investigative new drug (IND) application to initiate a Phase I clinical trial of ICT-121, IMUC's novel dendritic-cell-based vaccine targeting CD-133, an antigen that is highly expressed by multiple solid tumors.
› Verified 8 days ago
| Provider Name | Nathan Andrew Milender |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1699104711 PECOS PAC ID: 1254568470 Enrollment ID: I20131216000416 |
News Archive
Researchers at the University of Pennsylvania School of Medicine have determined how serotonin decreases the body's sensitivity to light and that exposure to constant darkness leads to a decrease in serotonin levels in the brain of fruit flies.
Diabetes in Control (http://www.diabetesincontrol.com), an e-newsletter dedicated to keeping clinicians current with the rapid changes in diabetes care, expands its quest to provide them with the best tools for their practice.
A significant discovery in the development of next-generation antibiotics has been made by Scottish biotechnology company Aquapharm.
A new Associated Press-GfK poll shows the strong emotions against President Barack Obama's health overhaul may be subsiding. Meanwhile, even as the industry's trade groups remain somewhat neutral on the law's future, pre-repeal groups are stepping up lobbying efforts.
ImmunoCellular Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has given clearance to a physician sponsored investigative new drug (IND) application to initiate a Phase I clinical trial of ICT-121, IMUC's novel dendritic-cell-based vaccine targeting CD-133, an antigen that is highly expressed by multiple solid tumors.
› Verified 8 days ago
| Provider Name | Nancy Strong |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1164863155 PECOS PAC ID: 7719119460 Enrollment ID: I20140410001268 |
News Archive
Researchers at the University of Pennsylvania School of Medicine have determined how serotonin decreases the body's sensitivity to light and that exposure to constant darkness leads to a decrease in serotonin levels in the brain of fruit flies.
Diabetes in Control (http://www.diabetesincontrol.com), an e-newsletter dedicated to keeping clinicians current with the rapid changes in diabetes care, expands its quest to provide them with the best tools for their practice.
A significant discovery in the development of next-generation antibiotics has been made by Scottish biotechnology company Aquapharm.
A new Associated Press-GfK poll shows the strong emotions against President Barack Obama's health overhaul may be subsiding. Meanwhile, even as the industry's trade groups remain somewhat neutral on the law's future, pre-repeal groups are stepping up lobbying efforts.
ImmunoCellular Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has given clearance to a physician sponsored investigative new drug (IND) application to initiate a Phase I clinical trial of ICT-121, IMUC's novel dendritic-cell-based vaccine targeting CD-133, an antigen that is highly expressed by multiple solid tumors.
› Verified 8 days ago
| Provider Name | Heidi Ann Robertson |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1568663797 PECOS PAC ID: 2264325331 Enrollment ID: I20141010000143 |
News Archive
Researchers at the University of Pennsylvania School of Medicine have determined how serotonin decreases the body's sensitivity to light and that exposure to constant darkness leads to a decrease in serotonin levels in the brain of fruit flies.
Diabetes in Control (http://www.diabetesincontrol.com), an e-newsletter dedicated to keeping clinicians current with the rapid changes in diabetes care, expands its quest to provide them with the best tools for their practice.
A significant discovery in the development of next-generation antibiotics has been made by Scottish biotechnology company Aquapharm.
A new Associated Press-GfK poll shows the strong emotions against President Barack Obama's health overhaul may be subsiding. Meanwhile, even as the industry's trade groups remain somewhat neutral on the law's future, pre-repeal groups are stepping up lobbying efforts.
ImmunoCellular Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has given clearance to a physician sponsored investigative new drug (IND) application to initiate a Phase I clinical trial of ICT-121, IMUC's novel dendritic-cell-based vaccine targeting CD-133, an antigen that is highly expressed by multiple solid tumors.
› Verified 8 days ago
| Provider Name | Joshua Timothy Kasper |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1376022384 PECOS PAC ID: 4880945914 Enrollment ID: I20180928000200 |
News Archive
Researchers at the University of Pennsylvania School of Medicine have determined how serotonin decreases the body's sensitivity to light and that exposure to constant darkness leads to a decrease in serotonin levels in the brain of fruit flies.
Diabetes in Control (http://www.diabetesincontrol.com), an e-newsletter dedicated to keeping clinicians current with the rapid changes in diabetes care, expands its quest to provide them with the best tools for their practice.
A significant discovery in the development of next-generation antibiotics has been made by Scottish biotechnology company Aquapharm.
A new Associated Press-GfK poll shows the strong emotions against President Barack Obama's health overhaul may be subsiding. Meanwhile, even as the industry's trade groups remain somewhat neutral on the law's future, pre-repeal groups are stepping up lobbying efforts.
ImmunoCellular Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has given clearance to a physician sponsored investigative new drug (IND) application to initiate a Phase I clinical trial of ICT-121, IMUC's novel dendritic-cell-based vaccine targeting CD-133, an antigen that is highly expressed by multiple solid tumors.
› Verified 8 days ago
| Provider Name | Olamide Enitan Larkin |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1518526458 PECOS PAC ID: 0749511939 Enrollment ID: I20191021001160 |
News Archive
Researchers at the University of Pennsylvania School of Medicine have determined how serotonin decreases the body's sensitivity to light and that exposure to constant darkness leads to a decrease in serotonin levels in the brain of fruit flies.
Diabetes in Control (http://www.diabetesincontrol.com), an e-newsletter dedicated to keeping clinicians current with the rapid changes in diabetes care, expands its quest to provide them with the best tools for their practice.
A significant discovery in the development of next-generation antibiotics has been made by Scottish biotechnology company Aquapharm.
A new Associated Press-GfK poll shows the strong emotions against President Barack Obama's health overhaul may be subsiding. Meanwhile, even as the industry's trade groups remain somewhat neutral on the law's future, pre-repeal groups are stepping up lobbying efforts.
ImmunoCellular Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has given clearance to a physician sponsored investigative new drug (IND) application to initiate a Phase I clinical trial of ICT-121, IMUC's novel dendritic-cell-based vaccine targeting CD-133, an antigen that is highly expressed by multiple solid tumors.
› Verified 8 days ago
News Archive
Researchers at the University of Pennsylvania School of Medicine have determined how serotonin decreases the body's sensitivity to light and that exposure to constant darkness leads to a decrease in serotonin levels in the brain of fruit flies.
Diabetes in Control (http://www.diabetesincontrol.com), an e-newsletter dedicated to keeping clinicians current with the rapid changes in diabetes care, expands its quest to provide them with the best tools for their practice.
A significant discovery in the development of next-generation antibiotics has been made by Scottish biotechnology company Aquapharm.
A new Associated Press-GfK poll shows the strong emotions against President Barack Obama's health overhaul may be subsiding. Meanwhile, even as the industry's trade groups remain somewhat neutral on the law's future, pre-repeal groups are stepping up lobbying efforts.
ImmunoCellular Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has given clearance to a physician sponsored investigative new drug (IND) application to initiate a Phase I clinical trial of ICT-121, IMUC's novel dendritic-cell-based vaccine targeting CD-133, an antigen that is highly expressed by multiple solid tumors.
› Verified 8 days ago
Healthpartners Specialty Center Woodbury Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 233 Radio Dr, Woodbury, MN 55125 Phone: 651-254-7400 | |
Ilko Family Medicine Pa Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1687 Woodlane Dr, Suite 102, Woodbury, MN 55125 Phone: 651-209-6685 Fax: 651-209-1680 | |
Woodbury Obstetrics & Gynecology Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 8360 City Centre Dr, Suite 120, Woodbury, MN 55125 Phone: 651-739-2182 Fax: 651-739-2045 | |
Shriners Children's Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 215 Radio Dr Ste 100, Woodbury, MN 55125 Phone: 612-596-6100 | |
Future Health Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 8362 Tamarack Vlg Ste 119-401, Woodbury, MN 55125 Phone: 952-541-7157 | |
Central Pediatrics, P.a. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 9680 Tamarack Rd Ste 100, Woodbury, MN 55125 Phone: 651-738-0470 Fax: 651-731-5031 | |
Minnhealth - Woodbury Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 8325 City Centre Dr, Woodbury, MN 55125 Phone: 651-731-0859 Fax: 651-731-0976 |